CA2302627A1 - Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques - Google Patents

Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques Download PDF

Info

Publication number: CA2302627A1
Authority: CA; Canada
Prior art keywords: cells; aenac; expression; dbcamp; dexamethasone
Prior art date: 2000-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2302627

Other languages

English (en)

Inventor

Rashmi Kothary

Andre Dagenais

Yves Berthiaume

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Centre Hospitalier de lUniversite de Montreal CHUM

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-23

Filing date

2000-03-23

Publication date

2001-09-23

2000-03-23 Application filed by Centre Hospitalier de lUniversite de Montreal CHUM filed Critical Centre Hospitalier de lUniversite de Montreal CHUM

2000-03-23 Priority to CA 2302627 priority Critical patent/CA2302627A1/fr

2001-09-23 Publication of CA2302627A1 publication Critical patent/CA2302627A1/fr

Status Abandoned legal-status Critical Current

Links

108700008625 Reporter Genes Proteins 0.000 title claims abstract description 20
238000012216 screening Methods 0.000 title claims abstract description 13
239000003814 drug Substances 0.000 title description 8
239000011734 sodium Substances 0.000 claims abstract description 116
229910052708 sodium Inorganic materials 0.000 claims abstract description 27
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 26
150000001875 compounds Chemical class 0.000 claims abstract description 22
108090000140 Epithelial Sodium Channels Proteins 0.000 claims abstract description 18
210000004027 cell Anatomy 0.000 claims description 139
230000014509 gene expression Effects 0.000 claims description 131
108090000623 proteins and genes Proteins 0.000 claims description 61
238000000034 method Methods 0.000 claims description 16
210000002919 epithelial cell Anatomy 0.000 claims description 15
108020004414 DNA Proteins 0.000 claims description 14
230000001105 regulatory effect Effects 0.000 claims description 14
239000012634 fragment Substances 0.000 claims description 13
238000012360 testing method Methods 0.000 claims description 8
206010037423 Pulmonary oedema Diseases 0.000 claims description 6
108010052164 Sodium Channels Proteins 0.000 claims description 4
210000003292 kidney cell Anatomy 0.000 claims description 4
150000007523 nucleic acids Chemical group 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 3
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
102000018674 Sodium Channels Human genes 0.000 claims description 3
210000005265 lung cell Anatomy 0.000 claims description 3
230000009103 reabsorption Effects 0.000 claims description 3
102000052510 DNA-Binding Proteins Human genes 0.000 claims description 2
108700020911 DNA-Binding Proteins Proteins 0.000 claims description 2
206010041277 Sodium retention Diseases 0.000 claims description 2
239000013604 expression vector Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 abstract description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
201000010099 disease Diseases 0.000 abstract description 2
208000035475 disorder Diseases 0.000 abstract description 2
230000002159 abnormal effect Effects 0.000 abstract 1
230000014759 maintenance of location Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 description 126
229960005263 bucladesine Drugs 0.000 description 108
CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 108
229960003957 dexamethasone Drugs 0.000 description 106
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 106
210000004072 lung Anatomy 0.000 description 51
230000000694 effects Effects 0.000 description 50
238000011282 treatment Methods 0.000 description 49
210000002588 alveolar type II cell Anatomy 0.000 description 42
241000700159 Rattus Species 0.000 description 32
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 32
230000035897 transcription Effects 0.000 description 29
238000013518 transcription Methods 0.000 description 29
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 26
241000699666 Mus <mouse, genus> Species 0.000 description 25
230000032258 transport Effects 0.000 description 23
230000001605 fetal effect Effects 0.000 description 18
108091006146 Channels Proteins 0.000 description 17
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 17
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 16
229960002576 amiloride Drugs 0.000 description 16
108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
108010092160 Dactinomycin Proteins 0.000 description 13
238000000636 Northern blotting Methods 0.000 description 13
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 13
229960000640 dactinomycin Drugs 0.000 description 13
102000003837 Epithelial Sodium Channels Human genes 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
108700009124 Transcription Initiation Site Proteins 0.000 description 11
230000001965 increasing effect Effects 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
238000013519 translation Methods 0.000 description 10
239000013598 vector Substances 0.000 description 10
108020005029 5' Flanking Region Proteins 0.000 description 9
230000033228 biological regulation Effects 0.000 description 9
239000012091 fetal bovine serum Substances 0.000 description 9
210000002821 alveolar epithelial cell Anatomy 0.000 description 8
230000027455 binding Effects 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
108020003589 5' Untranslated Regions Proteins 0.000 description 7
108091023040 Transcription factor Proteins 0.000 description 7
102000040945 Transcription factor Human genes 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
239000012528 membrane Substances 0.000 description 7
238000001890 transfection Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
230000000996 additive effect Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
210000000981 epithelium Anatomy 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
239000011575 calcium Substances 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108020004463 18S ribosomal RNA Proteins 0.000 description 4
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 4
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 4
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 4
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 4
102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 4
229960002478 aldosterone Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
239000003862 glucocorticoid Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
101150055766 cat gene Proteins 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000000763 evoking effect Effects 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
230000000222 hyperoxic effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000007758 minimum essential medium Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
208000005333 pulmonary edema Diseases 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000005026 transcription initiation Effects 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
238000011870 unpaired t-test Methods 0.000 description 3
108091006112 ATPases Proteins 0.000 description 2
102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
108700026226 TATA Box Proteins 0.000 description 2
102100023132 Transcription factor Jun Human genes 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
239000000048 adrenergic agonist Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000037427 ion transport Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000001985 kidney epithelial cell Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
230000005868 ontogenesis Effects 0.000 description 2
238000006213 oxygenation reaction Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
230000008844 regulatory mechanism Effects 0.000 description 2
238000003571 reporter gene assay Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
239000012096 transfection reagent Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
108050004195 AP-1 transcription factor Proteins 0.000 description 1
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
240000004246 Agave americana Species 0.000 description 1
101100440894 Arabidopsis thaliana CP33 gene Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
108091005462 Cation channels Proteins 0.000 description 1
-1 Cationic lipid Chemical class 0.000 description 1
229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
108700004996 Drosophila Na Proteins 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
102100031690 Erythroid transcription factor Human genes 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108010028165 GATA1 Transcription Factor Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102100033417 Glucocorticoid receptor Human genes 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
206010058490 Hyperoxia Diseases 0.000 description 1
102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
101150114843 Mgll gene Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 1
102100025803 Progesterone receptor Human genes 0.000 description 1
108010018070 Proto-Oncogene Proteins c-ets Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
244000166550 Strophanthus gratus Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
101710189834 Transcription factor AP-2-alpha Proteins 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000269368 Xenopus laevis Species 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000000296 active ion transport Effects 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
238000013019 agitation Methods 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
210000000424 bronchial epithelial cell Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
YDMCWONVABEGBK-UHFFFAOYSA-N carbamimidoylazanium;phenoxide Chemical compound NC(N)=N.OC1=CC=CC=C1 YDMCWONVABEGBK-UHFFFAOYSA-N 0.000 description 1
OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
230000029215 cell volume homeostasis Effects 0.000 description 1
230000004640 cellular pathway Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000009025 developmental regulation Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
230000005584 early death Effects 0.000 description 1
230000003503 early effect Effects 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
238000005562 fading Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007040 lung development Effects 0.000 description 1
230000012976 mRNA stabilization Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
108700024542 myc Genes Proteins 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
229960003343 ouabain Drugs 0.000 description 1
210000003681 parotid gland Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000009984 peri-natal effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
208000007750 pseudohypoaldosteronism Diseases 0.000 description 1
108700013540 rat Wwc1 Proteins 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000000580 secretagogue effect Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
108010042188 transcription factor PEA3 Proteins 0.000 description 1
230000022846 transcriptional attenuation Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000018889 transepithelial transport Effects 0.000 description 1
230000009495 transient activation Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2302627 2000-03-23 2000-03-23 Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques Abandoned CA2302627A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2302627 CA2302627A1 (fr)	2000-03-23	2000-03-23	Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2302627 CA2302627A1 (fr)	2000-03-23	2000-03-23	Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques

Publications (1)

Publication Number	Publication Date
CA2302627A1 true CA2302627A1 (fr)	2001-09-23

Family

ID=4165659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2302627 Abandoned CA2302627A1 (fr)	2000-03-23	2000-03-23	Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques

Country Status (1)

Country	Link
CA (1)	CA2302627A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004089423A3 (fr) *	2003-03-31	2005-04-21	Univ Iowa Res Found	Therapie pharmaco-genique des troubles associes au canal sodique epithelial
US7122335B1 (en)	1999-06-08	2006-10-17	University Of Iowa Research Foundation	Compounds and methods to enhance rAAV transduction
WO2007042776A1 (fr) *	2005-10-07	2007-04-19	Imperial College Innovations Limited	Modulateurs de la voie de signalisation purinergique pour traiter l'homeostasie du sodium, l'hypertension et l'hyperaldosteronisme
US8846030B2 (en)	1999-06-08	2014-09-30	University Of Iowa Research Foundation	Compounds and methods to enhance rAAV transduction
US11684679B2 (en)	2016-03-07	2023-06-27	University Of Iowa Research Foundation	AAV-mediated expression using a synthetic promoter and enhancer
US11702672B2 (en)	2016-02-08	2023-07-18	University Of Iowa Research Foundation	Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11999965B2 (en)	2017-01-13	2024-06-04	University Of Iowa Research Foundation	Bocaparvovirus small noncoding RNA and uses thereof
CN119061023A (zh) *	2024-10-30	2024-12-03	河北省农林科学院石家庄果树研究所	一种猕猴桃抗旱基因AeNAC17及其应用
US12173305B2 (en)	2016-05-26	2024-12-24	University Of Iowa Research Foundation	cis and trans requirements for terminal resolution of human bocavirus 1

2000
- 2000-03-23 CA CA 2302627 patent/CA2302627A1/fr not_active Abandoned

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7122335B1 (en)	1999-06-08	2006-10-17	University Of Iowa Research Foundation	Compounds and methods to enhance rAAV transduction
US8846030B2 (en)	1999-06-08	2014-09-30	University Of Iowa Research Foundation	Compounds and methods to enhance rAAV transduction
WO2004089423A3 (fr) *	2003-03-31	2005-04-21	Univ Iowa Res Found	Therapie pharmaco-genique des troubles associes au canal sodique epithelial
US7749491B2 (en)	2003-03-31	2010-07-06	University Of Iowa Research Foundation	Compounds and methods to enhance rAAV transduction
WO2007042776A1 (fr) *	2005-10-07	2007-04-19	Imperial College Innovations Limited	Modulateurs de la voie de signalisation purinergique pour traiter l'homeostasie du sodium, l'hypertension et l'hyperaldosteronisme
GB2446735A (en) *	2005-10-07	2008-08-20	Imp College Innovations Ltd	Modulators of the purinergic signalling pathway for treating sodium homeostatis hypertension and aldosteronism
US11702672B2 (en)	2016-02-08	2023-07-18	University Of Iowa Research Foundation	Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en)	2016-03-07	2023-06-27	University Of Iowa Research Foundation	AAV-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en)	2016-05-26	2024-12-24	University Of Iowa Research Foundation	cis and trans requirements for terminal resolution of human bocavirus 1
US11999965B2 (en)	2017-01-13	2024-06-04	University Of Iowa Research Foundation	Bocaparvovirus small noncoding RNA and uses thereof
CN119061023A (zh) *	2024-10-30	2024-12-03	河北省农林科学院石家庄果树研究所	一种猕猴桃抗旱基因AeNAC17及其应用

Legal Events

Date	Code	Title	Description
2002-06-26	FZDE	Dead

Publication	Publication Date	Title
Dagenais et al.	2001	Modulation of α-ENaC and α1-Na+-K+-ATPase by cAMP and dexamethasone in alveolar epithelial cells
Khachigian et al.	1995	Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells
Iraburu et al.	2000	Tumor necrosis factor α down‐regulates expression of the α1 (I) collagen gene in rat hepatic stellate cells through a p20C/EBPβ‐and C/EBPδ‐dependent mechanism
Shimano et al.	1997	Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells.
Otulakowski et al.	1999	Structure and hormone responsiveness of the gene encoding the α-subunit of the rat amiloride-sensitive epithelial sodium channel
Hirashima et al.	2003	Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway
Quehenberger et al.	2000	Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells.
Munsch et al.	2000	Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis
Marshall et al.	2008	Mighty is a novel promyogenic factor in skeletal myogenesis
Sasner et al.	1996	Distinct N-Methyl—aspartate Receptor 2B Subunit Gene Sequences Confer Neural and Developmental Specific Expression
Gronowski et al.	1995	Rapid changes in gene expression after in vivo growth hormone treatment
Garcia-Montero et al.	2001	Expression of the stress-induced p8 mRNA is transiently activated after culture medium change
CA2302627A1 (fr)	2001-09-23	Constructions comprenant le promoteur du canal sodique epithelial et un gene rapporteur pour le criblage de produits pharmaceutiques
Kolla et al.	1999	Identification of a mineralocorticoid/glucocorticoid response element in the human Na/K ATPase α1 gene promoter
Chabot et al.	1999	Downregulation of epithelial sodium channel (ENaC) by CFTR co-expressed in Xenopus oocytes is independent of Cl− conductance
Boutillier et al.	1998	Transcriptional activation of the proopiomelanocortin gene by cyclic AMP-responsive element binding protein
Iñiguez et al.	1994	Characterization of the promoter region and flanking sequences of the neuron-specific gene RC3 (neurogranin)
Jones et al.	1999	Molecular characterisation of cloned bradykinin B1 receptors from rat and human
Winklehner-Jennewein et al.	1998	A distal enhancer region in the human β-casein gene mediates the response to prolactin and glucocorticoid hormones
US20080014585A1 (en)	2008-01-17	Synergistic activation of regulatory elements by rel proteins and a steroid receptor
Boffa et al.	2002	A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor
US5753431A (en)	1998-05-19	Cholesterol 7 α-hydroxdylase gene regulatory elements and transcription factors
Padines-Figuères et al.	1990	Transcriptional control of the expression of lipoprotein lipase gene by growth hormone in preadipocyte Ob1771 cells.
Dong et al.	1995	Promoter region of the transcriptional unit for human α1‐chimaerin, a neuron‐specific GTPase‐activating protein for p21rac
Lu et al.	1999	Antisense knock out of the inositol 1, 3, 4, 5-tetrakisphosphate receptor GAP1IP4BP in the human erythroleukemia cell line leads to the appearance of intermediate conductance K (Ca) channels that hyperpolarize the membrane and enhance calcium influx